MedTrace Logo

Polymorphism of beta2-adrenoceptor and Regular Use of Formoterol in Asthma

NCT01786616 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2013-02-08

No results posted yet for this study

Summary

Polymorphism at codon 16 of the beta2-adrenoceptor (beta2-AR) affects the responsiveness to salmeterol in asthmatics. Data concerning formoterol are more controversial in literature. The aim of this study was to verify whether homozygote for arginine-16 (ArgArg16) and homozygote for glycine-16 (GlyGly16) genotypes differently influence the long-term responsiveness to formoterol.

Conditions

Interventions

DRUG

Formoterol

Sponsors & Collaborators

  • Catholic University, Italy

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-01-31
Primary Completion
2010-04-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01786616 on ClinicalTrials.gov